The failure to clinch a licensing contract for the flagship product AutoloGel from a top-20 global pharmaceutical company continues to haunt the fully integrated regenerative medicine company Cytomedix (OTC: CMXI). The company’s share price continued its downward spiral by another 9% amidst high volume. Cytomedix, the developer of platelet and adult stem cell technologies for […]
CMXI
Cytomedix Has Traders Reaching For The Dramimine (CMXI)
After gapping higher eight days ago on news that Medicare would cover its Autolougous PRP Gel in the treatment of chronic wounds, shares of Cytomedix (OTC: CMXI) gave back all the gains from last week and then some. The reason for the selling pressure today appears to lie in how traders interpreted the company’s second […]
Cytomedix Share Price Surges After Coverage Determination Granted by CMS (CMXI)
Cytomedix (OTC: CMXI) staged a huge rally in today’s trading session after informing the public that the Center for Medicare & Medicaid Services (CMS) granted Coverage with Evidence Development (CED) for the Cytomedix AutoloGel products. Today’s press release mentions that the Centers for Medicare & Medicaid Services issued a National Coverage Determination (NCD) on August 2, […]
Medicare Coverage Heals A Painful Summer For Cytomedix (CMXI)
A dismal summer for Cytomedix (OTC: CMXI) stock suddenly turned a little brighter today. The Centers for Medicare and Medicaid Services announced that they had approved coverage for autologous blood-derived products (the patient’s own blood) used in the treatment of chronic wounds specifically resulting from diabetes and pressure or venous wounds. Cytomedix develops and sells regenerative therapies including […]
